FFO
HAE icon

Fortitude Family Office’s Haemonetics HAE Stock Holding History

Fortitude Family Office’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.97K Buy
133
+111
+505% +$7.13K ﹤0.01% 773
2026
Q1 		$1.24K Buy
22
+12
+120% +$782 ﹤0.01% 1451
2025
Q4 		$802 Sell
10
-1
-9% -$67 ﹤0.01% 1543
2025
Q3 		$536 Sell
11
-1
-8% -$62 ﹤0.01% 1779
2025
Q2 		$895 Buy
+12
New +$795 ﹤0.01% 1570

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fortitude Family Office's HAE Position: Q2 2026 in Review

Fortitude Family Office increased its Haemonetics (HAE) stake by 505% in Q2 2026, buying an estimated $7.13K and bringing the position to 133 shares worth $9.97K. The position accounts for ﹤0.01% of the portfolio, ranked #773.

Fortitude Family Office first reported a position in HAE in Q2 2025 and has held it in 5 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Fortitude Family Office held 133 shares of Haemonetics worth $9.97K as of Q2 2026.
  • Fortitude Family Office bought 111 Haemonetics shares in Q2 2026, an estimated $7.13K.
  • Haemonetics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #773 holding.
  • Fortitude Family Office first reported a position in Haemonetics in Q2 2025 and has held it in 5 quarters since.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.